Trial Profile
Phase II trial of rituximab-CHOP (R-CHOP) [cyclophosphamide, doxorubicin, vincristine, and prednisone] plus GM-CSF [granulocyte macrophage colony stimulating factors] for previously untreated diffuse large cell lymphoma in the elderly.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Granulocyte-macrophage colony-stimulating factors; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 10 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from active, no longer recruiting to completed
- 12 May 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.